SynthesisEuropean respiratory review : an official journal of the European Respiratory Society2024
A systematic literature review of the clinical and socioeconomic burden of bronchiectasis.
Synthesis in European respiratory review : an official journal of the European Respiratory Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Obstructive Sleep Apnea in Bronchiectasis: Prevalence, Risk Factors and Clinical Implications-A Systematic Review and Meta-Analysis.Journal of sleep research · 2026Pooled it
- Health-related quality of life and associated factors in children with bronchiectasis: A systematic review.European journal of pediatrics · 2026Pooled it
- The European respiratory society guideline for adult bronchiectasis 2025: summary and implementation guide for primary care.NPJ primary care respiratory medicine · 2026Guideline
- Mucoactive agents in bronchiectasis: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Bronchiectasis in children: a systematic review of cytokine profile, immune cell phenotypes and microbiota in bronchoalveolar lavage fluid.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Patient report outcome measures for Spanish-speaking adults with bronchiectasis: systematic review of measurement properties.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Pooled it
- Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding study.The European respiratory journal · 2025Trial
- Patient-Reported Outcome scale for Bronchiectasis (BE-PRO): development and validation in China.Annals of medicine · 2026Article
- The dipeptidyl peptidase 1 inhibition landscape in bronchiectasis and its future direction.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Exacerbation Burden and Peripheral Airway Dysfunction as Determinants of Quality of Life in Bronchiectasis: Insights from Impulse Oscillometry.Medicina (Kaunas, Lithuania) · 2026Observational
- An interpretable prognostic model for early unfavorable outcomes after bronchiectasis surgery.BMC pulmonary medicine · 2026Article
- Resource impact of bronchiectasis and associated exacerbations: based on a 5-year prospective observational cohort study (BronchUK).BMJ open respiratory research · 2026Observational
- Body Composition and Muscle Function in Bronchiectasis: A Comparative Longitudinal Study.Respirology (Carlton, Vic.) · 2026Article
- The importance of symptoms in bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Article
- The European Respiratory Society guideline for management of adult bronchiectasis: clinical summary.Breathe (Sheffield, England) · 2026Review
- Azithromycin on serum FeNO, IgE, and eosinophil levels in bronchiectasis patients.Caspian journal of internal medicine · 2026Article
- Risk factors and prediction model for chronic bacterial infection in stable bronchiectasis in Shanghai, China.Frontiers in medicine · 2026Article
- Inhaled Corticosteroid Use and Risk ofJournal of clinical medicine · 2025Article
- Sputum metagenomics in bronchiectasis reveals pan-European variation: an EMBARC-BRIDGE study.The European respiratory journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe overall burden of bronchiectasis on patients and healthcare systems has not been comprehensively described. Here, we present the findings of a systematic literature review that assessed the clinical and socioeconomic burden of bronchiectasis with subanalyses by aetiology (PROSPERO registration: CRD42023404162).
methodsEmbase, MEDLINE and the Cochrane Library were searched for publications relating to bronchiectasis disease burden (December 2017-December 2022). Journal articles and congress abstracts reporting on observational studies, randomised controlled trials and registry studies were included. Editorials, narrative reviews and systematic literature reviews were included to identify primary studies. PRISMA guidelines were followed.
results1585 unique publications were identified, of which 587 full texts were screened and 149 were included. A further 189 citations were included from reference lists of editorials and reviews, resulting in 338 total publications. Commonly reported symptoms and complications included dyspnoea, cough, wheezing, sputum production, haemoptysis and exacerbations. Disease severity across several indices and increased mortality compared with the general population was reported. Bronchiectasis impacted quality of life across several patient-reported outcomes, with patients experiencing fatigue, anxiety and depression. Healthcare resource utilisation was considerable and substantial medical costs related to hospitalisations, treatments and emergency department and outpatient visits were accrued. Indirect costs included sick pay and lost income.
conclusionsBronchiectasis causes significant clinical and socioeconomic burden. Disease-modifying therapies that reduce symptoms, improve quality of life and reduce both healthcare resource utilisation and overall costs are needed. Further systematic analyses of specific aetiologies and paediatric disease may provide more insight into unmet therapeutic needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.